These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 11415906)

  • 1. Dynamic contrast-enhanced T2*-weighted MR imaging of tumefactive demyelinating lesions.
    Cha S; Pierce S; Knopp EA; Johnson G; Yang C; Ton A; Litt AW; Zagzag D
    AJNR Am J Neuroradiol; 2001; 22(6):1109-16. PubMed ID: 11415906
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Distinguishing tumefactive demyelinating lesions from glioma or central nervous system lymphoma: added value of unenhanced CT compared with conventional contrast-enhanced MR imaging.
    Kim DS; Na DG; Kim KH; Kim JH; Kim E; Yun BL; Chang KH
    Radiology; 2009 May; 251(2):467-75. PubMed ID: 19261924
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proton MR spectroscopy of tumefactive demyelinating lesions.
    Saindane AM; Cha S; Law M; Xue X; Knopp EA; Zagzag D
    AJNR Am J Neuroradiol; 2002 Sep; 23(8):1378-86. PubMed ID: 12223381
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Performance of Apparent Diffusion Coefficient Values and Conventional MRI Features in Differentiating Tumefactive Demyelinating Lesions From Primary Brain Neoplasms.
    Mabray MC; Cohen BA; Villanueva-Meyer JE; Valles FE; Barajas RF; Rubenstein JL; Cha S
    AJR Am J Roentgenol; 2015 Nov; 205(5):1075-85. PubMed ID: 26496556
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relative cerebral blood volume values to differentiate high-grade glioma recurrence from posttreatment radiation effect: direct correlation between image-guided tissue histopathology and localized dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging measurements.
    Hu LS; Baxter LC; Smith KA; Feuerstein BG; Karis JP; Eschbacher JM; Coons SW; Nakaji P; Yeh RF; Debbins J; Heiserman JE
    AJNR Am J Neuroradiol; 2009 Mar; 30(3):552-8. PubMed ID: 19056837
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of tumefactive demyelinating lesions using MR imaging and in-vivo proton MR spectroscopy.
    Malhotra HS; Jain KK; Agarwal A; Singh MK; Yadav SK; Husain M; Krishnani N; Gupta RK
    Mult Scler; 2009 Feb; 15(2):193-203. PubMed ID: 19181773
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MRI Findings in Tumefactive Demyelinating Lesions: A Systematic Review and Meta-Analysis.
    Suh CH; Kim HS; Jung SC; Choi CG; Kim SJ
    AJNR Am J Neuroradiol; 2018 Sep; 39(9):1643-1649. PubMed ID: 30115676
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Histogram analysis of apparent diffusion coefficient maps for differentiating primary CNS lymphomas from tumefactive demyelinating lesions.
    Lu SS; Kim SJ; Kim N; Kim HS; Choi CG; Lim YM
    AJR Am J Roentgenol; 2015 Apr; 204(4):827-34. PubMed ID: 25794073
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glial tumor grading and outcome prediction using dynamic spin-echo MR susceptibility mapping compared with conventional contrast-enhanced MR: confounding effect of elevated rCBV of oligodendrogliomas [corrected].
    Lev MH; Ozsunar Y; Henson JW; Rasheed AA; Barest GD; Harsh GR; Fitzek MM; Chiocca EA; Rabinov JD; Csavoy AN; Rosen BR; Hochberg FH; Schaefer PW; Gonzalez RG
    AJNR Am J Neuroradiol; 2004 Feb; 25(2):214-21. PubMed ID: 14970020
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of dynamic susceptibility contrast-enhanced perfusion MR imaging in differentiating between infectious and neoplastic focal brain lesions: results from a cohort of 100 consecutive patients.
    Floriano VH; Torres US; Spotti AR; Ferraz-Filho JR; Tognola WA
    PLoS One; 2013; 8(12):e81509. PubMed ID: 24324699
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dynamic contrast-enhanced T2*-weighted MR imaging of gliomatosis cerebri.
    Yang S; Wetzel S; Law M; Zagzag D; Cha S
    AJNR Am J Neuroradiol; 2002 Mar; 23(3):350-5. PubMed ID: 11900998
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Utility of proton MR spectroscopy for differentiating typical and atypical primary central nervous system lymphomas from tumefactive demyelinating lesions.
    Lu SS; Kim SJ; Kim HS; Choi CG; Lim YM; Kim EJ; Kim DY; Cho SH
    AJNR Am J Neuroradiol; 2014 Feb; 35(2):270-7. PubMed ID: 23928144
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Perfusion and diffusion MR imaging in enhancing malignant cerebral tumors.
    Calli C; Kitis O; Yunten N; Yurtseven T; Islekel S; Akalin T
    Eur J Radiol; 2006 Jun; 58(3):394-403. PubMed ID: 16527438
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correlation of relative permeability and relative cerebral blood volume in high-grade cerebral neoplasms.
    Provenzale JM; York G; Moya MG; Parks L; Choma M; Kealey S; Cole P; Serajuddin H
    AJR Am J Roentgenol; 2006 Oct; 187(4):1036-42. PubMed ID: 16985154
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glial neoplasms: dynamic contrast-enhanced T2*-weighted MR imaging.
    Knopp EA; Cha S; Johnson G; Mazumdar A; Golfinos JG; Zagzag D; Miller DC; Kelly PJ; Kricheff II
    Radiology; 1999 Jun; 211(3):791-8. PubMed ID: 10352608
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Can permeability measurements add to blood volume measurements in differentiating tumefactive demyelinating lesions from high grade gliomas using perfusion CT?
    Jain R; Ellika S; Lehman NL; Scarpace L; Schultz LR; Rock JP; Rosenblum M; Mikkelsen T
    J Neurooncol; 2010 May; 97(3):383-8. PubMed ID: 19830525
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dynamic contrast-enhanced susceptibility-weighted perfusion imaging of intracranial tumors: a study using a 3T MR scanner.
    Sentürk S; Oğuz KK; Cila A
    Diagn Interv Radiol; 2009 Mar; 15(1):3-12. PubMed ID: 19263367
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dynamic susceptibility contrast-enhanced perfusion and conventional MR imaging findings for adult patients with cerebral primitive neuroectodermal tumors.
    Law M; Kazmi K; Wetzel S; Wang E; Iacob C; Zagzag D; Golfinos JG; Johnson G
    AJNR Am J Neuroradiol; 2004; 25(6):997-1005. PubMed ID: 15205137
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumefactive demyelinating lesions: conventional and advanced magnetic resonance imaging.
    Enzinger C; Strasser-Fuchs S; Ropele S; Kapeller P; Kleinert R; Fazekas F
    Mult Scler; 2005 Apr; 11(2):135-9. PubMed ID: 15794384
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mass lesions in the brain: tumor or multiple sclerosis? Clinical and imaging characteristics and course from a single reference center.
    Kilic AK; Kurne AT; Oguz KK; Soylemezoglu F; Karabudak R
    Turk Neurosurg; 2013; 23(6):728-35. PubMed ID: 24310455
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.